U2AF1L4: A Potential Drug Target and Biomarker (G199746)

Target Name: U2AF1L4

NCBI ID: G199746

U2AF1L4

U2AF1L4: A Potential Drug Target and Biomarker

Uncovering new drug targets and biomarkers is a crucial aspect of drug development. It is the process of identifying potential therapeutic targets and biomarkers that can be used to treat various diseases, including cancer. One promising candidate for drug targeting and biomarker is U2AF1L4. U2AF1L4 is a gene that has been identified in various studies as a potential drug target and biomarker. In this article, we will discuss the potential drug targeting and biomarker properties of U2AF1L4.

Drug Targeting Properties of U2AF1L4

U2AF1L4 is a gene that is located on chromosome 11 and encodes for a protein known as U2AF1L4. This protein is involved in various cellular processes, including cell adhesion, migration, and invasion. U2AF1L4 has also been shown to play a role in the development and progression of various diseases, including cancer.

One of the promising aspects of U2AF1L4 as a drug target is its druggability. U2AF1L4 has been shown to have a unique structural profile that makes it a potential target for small molecules. The protein has a long amino acid sequence that is rich in positively charged amino acids, which makes it more susceptible to drug interactions. Additionally, U2AF1L4 has a high degree of cross-talk, which means that changes in the expression of its gene can affect various cellular processes, making it more vulnerable to drug intervention.

In addition to its druggability, U2AF1L4 has also been shown to have a unique expression pattern in various tissues and organs. For example, studies have shown that U2AF1L4 is highly expressed in the human pancreatic cancer tissue, and its expression level is also increased in the human colon cancer tissue. This suggests that U2AF1L4 may be a useful biomarker for pancreatic and colon cancer, respectively.

Biomarker Properties of U2AF1L4

In addition to its potential drug targeting properties, U2AF1L4 has also been shown to have potential as a biomarker. U2AF1L4 has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. This suggests that it may be a useful biomarker for various diseases, including cancer.

One of the promising aspects of U2AF1L4 as a biomarker is its expression pattern. Studies have shown that U2AF1L4 is highly expressed in various tissues and organs, including the pancreas, colon, and brain. Additionally, studies have shown that U2AF1L4 is downregulated in various diseases, including cancer. This suggests that U2AF1L4 may be a useful biomarker for detecting diseases at an early stage.

Another promising aspect of U2AF1L4 as a biomarker is its potential to be used for targeted therapies. The high degree of cross-talk between U2AF1L4 and other genes makes it more vulnerable to drug intervention. This suggests that U2AF1L4 may be a useful target for small molecules that can inhibit its function.

Conclusion

In conclusion, U2AF1L4 is a gene that has shown promise as a potential drug target and biomarker. Its unique structural profile, high degree of cross-talk, and potential to be used for targeted therapies make it an attractive candidate for drug development. Further studies are needed to confirm its potential as a drug target and biomarker.

Protein Name: U2 Small Nuclear RNA Auxiliary Factor 1 Like 4

Functions: RNA-binding protein that function as a pre-mRNA splicing factor. Plays a critical role in both constitutive and enhancer-dependent splicing by mediating protein-protein interactions and protein-RNA interactions required for accurate 3'-splice site selection. Acts by enhancing the binding of U2AF2 to weak pyrimidine tracts. Also participates in the regulation of alternative pre-mRNA splicing. Activates exon 5 skipping of PTPRC during T-cell activation; an event reversed by GFI1. Binds to RNA at the AG dinucleotide at the 3'-splice site (By similarity). Shows a preference for AGC or AGA (By similarity)

The "U2AF1L4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about U2AF1L4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets